Table 5.
Results from univariate Cox proportional hazards model assessing influence of de novo status, age at diagnosis (dx age), receiving surgery, ER status of primary tumor, race, treatment endocrine therapy, chemotherapy, radiation, bone-targeted therapy, and CDK inhibitors on overall survival (OS) and bone metastasis survival (BMS). *Mixed- refers to patients with tumors displaying both ILC and IDC subtypes.
| Parameter | OS |
BMS |
|||
|---|---|---|---|---|---|
| Hazard Ratio | P-value | Hazard Ratio | P-value | ||
| De novo Status | <0.0001 | 2.62 | 0.14 | 0.69 | |
| Age at Dx | 0.0003 | 1.03 | 0.11 | 1.01 | |
| Received Surgery (ref = yes) | 0.2 | 1.29 | 0.03 | 1.52 | |
| ER primary, n = 160 (ref = negative) | 0.03 | 0.5 | 0.001 | 0.32 | |
| Race | African American vs. Caucasian | 0.01 | 2.5 | 0.12 | 1.72 |
| Asian vs. Caucasian | 0.79 | 1.3 | 0.63 | 0.62 | |
| Endocrine Therapy (ref = no) | 0.13 | 0.59 | 0.0001 | 0.27 | |
| Chemotherapy (ref = no) | 0.1 | 3.32 | 0.16 | 2.8 | |
| Radiotherapy, n = 163 (ref = no) | 0.48 | 0.79 | 0.76 | 0.9 | |
| Bone-targeted therapy, n = 165 (ref = no) | 0.25 | 0.72 | 0.001 | 0.39 | |
| CDK inhibitor therapy (ref = no) | 0.08 | 0.7 | 0.003 | 0.56 | |
| Histological Subtype, n = 157 | ILC vs IDC | 0.32 | 1.4 | 0.81 | 1.1 |
| Mixed* vs IDC | 0.02 | 2.4 | 0.01 | 2.7 | |